<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="192645">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584402</url>
  </required_header>
  <id_info>
    <org_study_id>200715241</org_study_id>
    <nct_id>NCT00584402</nct_id>
  </id_info>
  <brief_title>Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation</brief_title>
  <official_title>Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the Definity (perflutren lipid
      microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors
      (hepatomas &amp; metastases) within the liver.

      Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with
      contrast-enhanced sonography

      Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the
      conspicuity of small tumors on contrast-enhanced sonography
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 75 patients (age 18 years of age or older) will be enrolled from the population
      of patients who present for ultrasound-guided radiofrequency ablation (RFA) of CT or
      MRI-confirmed multiple primary hepatocellular carcinoma (HCC) or metastatic carcinoma, with
      at least one of the tumors being ≤ 1.5 cm in diameter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>estimation of the the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimation of the the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Contrast sonography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contrast-enhanced sonography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perflutren lipid microspheres</intervention_name>
    <description>IV in 0.1 cc doses, as needed, to enhance lesion conspicuity</description>
    <arm_group_label>Contrast sonography</arm_group_label>
    <other_name>Definity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary hepatocellular carcinoma (HCC) or secondary (metastatic)
             carcinoma of the liver who have been referred for ultrasound-guided radiofrequency
             ablation (RFA) treatment

          -  Recent (within 90 days) CT or MRI scan with report of one or more tumors ≤ 1.5 cm in
             diameter

          -  Patient is stable and is to be managed conservatively (i.e. non-surgically)

          -  18 years of age or older

          -  Ability and willingness to provide written informed consent

        Exclusion Criteria:

          -  Known or suspected cardiac shunt(s)

          -  Known sensitivity to octafluoropropane

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. McGahan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis School of Medicine Dept. of Radiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 19, 2012</lastchanged_date>
  <firstreceived_date>December 21, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>John McGahan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
